Experimental studies on targeting-therapy of "double bomb"-Mixed monoclonal antibodies immunoconjugates against hepatocellular carcinoma / 中华消化杂志

ABSTRACT

Two highly specific monoclonal antibodies with potentul affinity against hepatocellular carcinoma HAb18, HAb25 as carriers, 131I and adriamycin (ADM) as warhead "double bomb"-mixed monoclonal antibodies immunoconjugates(131I-HAb18-ADM)/(131I-HAb25-ADM) was prepared by indirectly conjugated with dextran T-40 and chloramine-T methods. The immunoconjugating rate to target cells was 42.5%, labelling rate 49.8%, and specific radioactivity 6.88?104Bq/?g. In vitro, (131I-HAb18-ADM)/(131I-HAb25-ADM) showed stronger selective cytotoxicity against target tumor cells than either HAb18-ADM, or 131I-HAb18, or HAb25-ADM, or 131I-HAb25 conjugate alone(P